Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | KCNK18 | Q7Z418 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703748 | 0.83 | SCN2A (0.53) | CYP3A4CYP2C9SCN2AIKBKBPIN1 | |
| SCHEMBL12761250 | 0.82 | GP6 (0.37) | — | |
| SCHEMBL270345 | 0.79 | XDH (0.47) | KIF11 | |
| SCHEMBL19736688 | 0.78 | KIF11 (0.32) | KIF11 | |
| SCHEMBL513232 | 0.77 | ALDH1A1 (0.44) | CYP2C9ACHEPIN1 | |
| SCHEMBL8336907 | 0.76 | NOTUM (0.32) | — | |
| SCHEMBL13713676 | 0.76 | KDM4E (0.37) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4655029 | 0.75 | GP6 (0.49) | CYP3A4CYP2C9CYP2C19 | |
| Water SCHEMBL10460296 | 0.75 | MRGPRX4 (0.37) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13525158 | 0.75 | ALDH1A1 (0.41) | CYP2C9PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | METREA BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| US-20220177443-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885RXRA 4158/4885RXRB 4289/4885 |
| US-20220177443-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, IKZF3 | KIF11 180/4885RXRA 2457/4885RXRB 2400/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885RXRA 4158/4885RXRB 4289/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | KIF11 1031/4885RXRA 2765/4885RXRB 3968/4885 |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | KIF11 4473/4885RXRA 1926/4885RXRB 1847/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KIF11 3097/4885RXRA 1953/4885RXRB 1964/4885 |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885RXRA 4158/4885RXRB 4289/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | KIF11 3097/4885RXRA 1953/4885RXRB 1964/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | KIF11 3097/4885RXRA 1953/4885RXRB 1964/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885RXRA 4158/4885RXRB 4289/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | KIF11 3653/4885RXRA 4158/4885RXRB 4289/4885 |
| US-20230339871-A1 | COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 | HSD17B1, HSD17B13, HSD17B11 | KIF11 3161/4885RXRA 1269/4885RXRB 807/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | KIF11 1678/4885RXRA 3697/4885RXRB 4148/4885 |
| US-20200317705-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | KIF11 2683/4885RXRA 4602/4885RXRB 4451/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | KIF11 410/4885RXRA 1903/4885RXRB 1967/4885 |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | KIF11 1038/4885RXRA 3207/4885RXRB 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.